Preclinical Roundup: CureVac gets CEPI funding for 2019 coronavirus; plus blockade of CD47-SIRPA for atherosclerosis, Stanford and IBM-CDHI

By BioCentury Staff | Feb 1, 2020 | 2:05 AM GMT
Editor's note: Updated on Feb 3, 2020 at 9:13 PM GMT
CureVac gets CEPI funding for 2019 coronavirus

The Coalition for Epidemic Preparedness Innovations and CureVac AG are extending a February 2019 collaboration to include a vaccine against the 2019-nCoV acute respiratory disease. The company will receive up to an additional $8.3 million in

Read the full 429 word article

How to gain access

Continue reading with a
two-week free trial.